CDK2 Inhibitor Dosing Regimens for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for appropriate and efficacious dosing regimens of the CDK2 inhibitor PF-07104091 as a monotherapy and in combination therapies for treating cancer, while maintaining an acceptable safety profile and minimizing adverse events.
Innovation Solution
The disclosure provides methods of treating cancer by administering a therapeutically effective amount of PF-07104091, either as a single agent or in combination with endocrine therapy agents such as aromatase inhibitors, SERDs, or SERMs, and/or EZH2 inhibitors, with specific dosing regimens ranging from about 75 mg to about 1000 mg per day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of CDK2 inhibitor PF-07104091 are administered to maximize antitumor efficacy, then cancer treatment effectiveness is improved, but adverse events and safety issues worsen
Solution Approach 1:
The patent implements dynamic dosing regimens that adjust the dose of PF-07104091 based on patient response and tolerability. The regimen evolves from initial dose escalation to maintenance dosing, allowing the treatment to adapt to the patient's physiological state and maximize efficacy while minimizing adverse events throughout the treatment course.
Solution Approach 2:
The patent systematically varies dosing parameters including dose amount (75-1000 mg per day), dosing frequency (once or twice daily), and treatment duration to optimize the balance between antitumor efficacy and safety. Different dosing regimens are established for monotherapy versus combination therapy scenarios.
2Device complexity
If CDK2 inhibitor PF-07104091 is used as monotherapy to simplify treatment, then device complexity is reduced, but treatment effectiveness worsens compared to combination therapy
Solution Approach 1:
The patent segments the treatment approach into distinct options: monotherapy with PF-07104091 for patients who cannot tolerate combination therapy or have specific clinical characteristics, and combination therapy with PF-07104091 plus endocrine therapy agents for patients who can tolerate and may benefit from more intensive treatment. This segmentation allows clinicians to select the appropriate complexity level based on patient needs.
Solution Approach 2:
The patent enables dynamic switching between monotherapy and combination therapy based on patient response and tolerability. Patients may start with combination therapy and be de-escalated to monotherapy if adverse events occur, or start with monotherapy and be escalated to combination therapy if response is insufficient, providing flexibility in managing treatment complexity.
3Reliability
If combination therapy with multiple agents is used to enhance antitumor activity, then treatment effectiveness is improved, but dosing regimen complexity and difficulty of administration worsen
Solution Approach 1:
The patent optimizes dosing parameters for combination therapy by establishing specific dosing schedules for PF-07104091 when administered with endocrine therapy agents or EZH2 inhibitors. The dosing frequency and timing are carefully calibrated to achieve synergistic antitumor effects while managing the complexity of multiple medication administrations.
Data Source
AI summary
The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent and/or a CDK4/6 inhibitor.